1. Li G., De Clercq E. (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV) // Nat. Rev. Drug Discov. V.19. No. 3. P. 149-150. DOI: 10.1038/d41573-020-00016-0

2. Hoffmann M., Kleine-Weber H., Schroeder S. et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor // Cell. V. 181. No. 2. P. 271-280. DOI: 10.1016/j.cell.2020.02.052

3. Beigel J.H., Tomashek K.M., Dodd L.E. et al. (2020) Remdesivir for the Treatment of Covid-19 - Final Report // N. Engl. J, Med. V. 383. No. 19. P. 1813-1826. DOI: 10.1056/NEJMoa2007764

4. Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 // Science. V. 367. No. 6485. P. 1444-1448. DOI: 10.1126/science.abb2762

5. Tay M.Z., Poh C.M., Rénia L., MacAry P.A., Ng L.F.P. (2020) The trinity of COVID-19: immunity, inflammation and intervention // Nat. Rev. Immunol. V. 20. No. 6. P. 363-374. DOI: 10.1038/s41577-020-0311-8

6. Shang J., Ye G., Shi K. et al. (2020) Structural basis of receptor recognition by SARS-CoV-2 // Nature. V. 581. No. 7807. P. 221-224. DOI: 10.1038/s41586-020-2179-y

7. Chu D.K., Akl E.A., Duda S. et al. (2020) Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis // Lancet. V. 395. No. 10242. P. 1973-1987. DOI: 10.1016/S0140-6736(20)31142-9

8. Jin Z., Du X., Xu Y. et al. (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors // Nature. V. 582. No. 7811. P. 289-293. DOI: 10.1038/s41586-020-2223-y

9. Chen Y., Liu Q., Guo D. (2020) Emerging coronaviruses: Genome structure, replication, and pathogenesis // J. Med. Virol. V. 92. No. 4. P. 418-423. DOI: 10.1002/jmv.25681

10. Bikdeli B., Madhavan M..V, Jimenez D. et al. (2020) COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review // J. Am. Coll. Cardiol. V. 75. No. 23. P. 2950-2973. DOI: 10.1016/j.jacc.2020.04.031

11. Zhang L., Lin D., Sun X. et al. (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors // Science. V. 368. No. 6489. P. 409-412. DOI: 10.1126/science.abb3405

12. Wang Q., Zhang Y., Wu L. et al. (2020) Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 // Cell. V. 181. No. P. 894-904. DOI: 10.1016/j.cell.2020.03.045

13. Shang J., Wan Y., Luo C. et al. (2020) Cell entry mechanisms of SARS-CoV-2 // Proc. Natl. Acad. Sci. U S A. V. 117. No. 21. P. 11727-11734. DOI: 10.1073/pnas.2003138117

14. Gordon D.E., Jang G.M., Bouhaddou M. et al. (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing // Nature. V. 583. No. 7816. P. 459-468. DOI: 10.1038/s41586-020-2286-9

15. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target // Intensive Care Med. V. 46. No. 4. P.586-590. DOI: 10.1007/s00134-020-05985-9

16. Sungnak W., Huang N., Bécavin C. et al. (2020) HCA Lung Biological Network. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes // Nat. Med. V. 26. No. 5. P. 681-687. DOI: 10.1038/s41591-020-0868-6

17. Connors J.M., Levy J.H. (2020) COVID-19 and its implications for thrombosis and anticoagulation // Blood. V. 135. No. 23. P. 2033-2040. DOI: 10.1182/blood.2020006000

18. Guy R.K. DiPaola R.S., Romanelli F., Dutch R.E. (2020) Rapid repurposing of drugs for COVID-19 // Science. V. 368. No. 6493 P.829-830. DOI: 10.1126/science.abb9332

19. Li Z., Li X., Huang Y.Y. et al. (2020) Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs // Proc. Natl. Acad. Sc.i U S A. V. 117. No. 44. P. 27381-27387. DOI: 10.1073/pnas.2010470117

20. Monteil V., Kwon H., Prado P. et al. (2020) Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. V. 181. No. 4. P. 905-913.e7. DOI: 10.1016/j.cell.2020.04.004

21. Moore J.B., June C.H. (2020) Cytokine release syndrome in severe COVID-19 // Science. V. 368. No. 6490. P. 473-474. DOI: 10.1126/science.abb8925

22. Rambaut A., Holmes E.C., O'Toole Á. et al. (2020) A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. // Nat. Microbiol. V. 5. No. 11. P. 1403-1407. DOI: 10.1038/s41564-020-0770-5

23. Kim D., Lee J.Y., Yang J.S., Kim J.W., Kim V.N., Chang H. (2020) The Architecture of SARS-CoV-2 Transcriptome // Cell. V. 181. No. 4. P. 914-921.e10. doi: 10.1016/j.cell.2020.04.011. DOI: 10.1016/j.cell.2020.04.011

24. Puelles V.G., Lütgehetmann M., Lindenmeyer M.T. et al. (2020) Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020 Aug 6;383(6):590-592. doi: 10.1056/NEJMc2011400 // N. Engl. J. Med. V. 383. No. 6. P. 590-592. doi: 10.1056/NEJMc2011400. DOI: 10.1056/NEJMc2011400

25. Thanh Le T., Andreadakis Z., Kumar A. et al. (2020) The COVID-19 vaccine development landscape // Nat. Rev. Drug Discov. V. 19. No. 5. P. 305-306. DOI: 10.1038/d41573-020-00073-5

26. Tai W., He L., Zhang X. et al. (2020) Trimeric receptor-binding domain of SARS-CoV-2 acts as a potent inhibitor of ACE2 receptor-mediated viral entry // Cell. Mol. Immunol. V. 17. No. 6. P. 613-620. DOI: 10.1038/s41423-020-0400-4

27. Ju B., Zhang Q., Ge J. et al. (2020) Human neutralizing antibodies elicited by SARS-CoV-2 infection // Nature. V. 584. No. 7819. P. 115-119. DOI: 10.1038/s41586-020-2380-z

28. Gao Y., Yan L., Huang Y. et al. (2020) Structure of the RNA-dependent RNA polymerase from COVID-19 virus // Science. V. 368. No. 6492. P. 779-782. DOI: 10.1126/science.abb7498

29. Cantuti-Castelvetri L., Ojha R., Pedro L.D. et al. (2020) Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity // Science. V. 370. No. 6518. P. 856-860. DOI: 10.1126/science.abd2985

30. Huang Y., Yang C., Xu X.F., Xu W., Liu S.W. (2020) Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 // Acta Pharmacol. Sin. V. 41. No. 9. P. 1141-1149. DOI: 10.1038/s41401-020-0485-4

31. Zarocostas J. (2020) How to fight an infodemic // Lancet. V. 395. No. 10225. P. 676. DOI: 10.1016/S0140-6736(20)30461-X

32. Gupta A., Madhavan M.V., Sehgal K. et al. (2020) Extrapulmonary manifestations of COVID-19 // Nat. Med. V. 26. No. 7. P. 1017-1032. DOI: 10.1038/s41591-020-0968-3

33. Li Q., Wu J., Nie J. et al. (2020) The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity // Cell. V. 182, No. 5. P. 1284-1294.e9. DOI: 10.1016/j.cell.2020.07.012

34. Riva L., Yuan S., Yin X. et al. (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing // Nature. V. 586. No. 7827. P. 113-119. DOI: 10.1038/s41586-020-2577-1

35. Gil C., Ginex T., Maestro I. et al. (2020) COVID-19: Drug Targets and Potential Treatments // J. Med. Chem. V. 63. No. 21. P. 12359-12386. DOI: 10.1021/acs.jmedchem.0c00606

36. Dong L., Hu S., Gao J. (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19) // Drug Discov. Ther. V. 14. No. 1. P. 58-60. DOI: 10.5582/ddt.2020.01012

37. Touret F., Gilles M., Barral K. et al. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication // Sci. Rep. V. 10. P. 13093. DOI: 10.1038/s41598-020-70143-6

38. Zhu W., Xu M., Chen C.Z. et al. (2020) 3CL Protease Inhibitors by a Quantitative High-Throughput Screening // ACS Pharmacol. Transl. Sci. V. 3. No. 5. P. 1008-1016. DOI: 10.1021/acsptsci.0c00108

39. Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M. (2020) Site-specific glycan analysis of the SARS-CoV-2 spike // Science. V. 369. No. 6501. P. 330-333. DOI: 10.1126/science.abb9983

40. Weston S., Coleman C.M., Haupt R. et al. (2020) Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo // J. Virol. V. 94. No. 21. P. e01218-20. DOI: 10.1128/JVI.01218-20

41. Dai W., Zhang B., Jiang X.M. et al. (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease // Science. V. 368. No. 6497. P. DOI: 10.1126/science.abb4489

42. Sadegh S., Matschinske J., Blumenthal D.B. et al. (2020) Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing // Nat. Commun. V. 11. P. 3518. DOI: 10.1038/s41467-020-17189-2

43. Pizzorno A., Padey B., Dubois J. et al. (2021) In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2 // Antiviral Res. V. 181. P. 104878. DOI: 10.1016/j.antiviral.2020.104878

44. Singh N., Decroly E., Khatib A.M., Villoutreix B.O. (2020) Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages // Eur. J. Pharm. Sci. V. 153. P. 105495. DOI: 10.1016/j.ejps.2020.105495

45. Matsuyama S., Nao N., Shirato K. et al. (2020) Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells // Proc. Natl. Acad. Sci. U S A. V. 117. No. 13. P. 7001-7003. DOI: 10.1073/pnas.2002589117

46. Stroylov V.S., Svitanko I.V. (2020) Computational identification of disulfiram and neratinib as putative SARS-CoV-2 main protease inhibitors // Mendeleev Communications. V. 30. No. 4. P. 419-420. DOI: 10.1016/j.mencom.2020.07.004

47. Nersisyan S., Shkurnikov M., Turchinovich A. et al. (2020) Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2 // PLoS One. V. 15. P. :e0235987. DOI: 10.1371/journal.pone.0235987

48. Nasonov E., Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19 // Biomed. Pharmacother. V. 131. P. 110698. DOI: 10.1016/j.biopha.2020.110698

49. Новиков Ф.Н. , Стройлов В.С. , Свитанько И.В. , Небольсин В.Е. (2020) Молекулярные основы патогенеза COVID-19 // Успехи химии. Т. 89. С. 858-878. DOI: 10.1070/RCR4961

50. Ionov N., Pogodin P., Poroikov V. (2029) Assessing the Prediction Quality of the Anti-SARS-CoV-2 Activity Using the D3Targets-2019-nCoV Web Service // Biomedical Chemistry: Research and Methods. V. 3. No. 4. P. e00140. DOI: 10.18097/BMCRM00140

51. Гомазков О.А. (2020) Эндотелий - мишень, которую выбирает коронавирус. Анализ молекулярных и патофизиологических механизмов COVID-19 // Москва: Из-во ИКАР. - 62 С. Ссылка

52. Скворцов В.С., Дружиловский Д.С., Веселовский А.В. (2020) Потенциальные ингибиторы протеазы 3СLpro вируса COVID-19: репозиционирование лекарств // Biomedical Chemistry: Research and Methods. Т. 3. С. e00124. DOI: 10.18097/BMCRM00124

53. Фисенко В.П., Чичкова Н.В. (2020) Современная пандемия COVID-19 и лекарственные средства // Экспериментальная и клиническая фармакология. Т. 83. С. 43-44. DOI: 10.30906/0869-2092-2020-83-4-43-44

1. Chen C.Z., Shinn P., Itkin Z. et al. (2021) Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2 // Front. Pharmacol. V. 11. P. 592737. DOI: 10.3389/fphar.2020.592737

2. MacRaild C.A., Mohammed M.U., Faheem, Murugesan S. et al. (2022) Systematic down-selection of repurposed drug candidates for COVID-19 // Int. J. Mol. Sci. V. 23. No. 19. P. 11851. DOI: 10.3390/ijms231911851

3. Hanson Q.M., Wilson K.M., Shen M., et al. (2020) Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay // ACS Pharmacol. Transl. Sci. V. 3. No. 6. P. 1352-1360. Published 2020 Nov 17. DOI: 10.1021/acsptsci.0c00161

4. WHO Solidarity Trial Consortium; Pan H., Peto R., Henao-Restrepo A.M. et al. (2021) Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results // N. Engl. J. Med. V. 384. No. 6. P. 497-511. DOI: 10.1056/NEJMoa2023184

5. Zhao L., Li S., Zhong W. (2022) Mechanism of action of small-molecule agents in ongoing clinical trials for SARS-CoV-2: A review // Front. Pharmacol. V. 13. P. 840639. DOI: 10.3389/fphar.2022.840639

6. Nalbandian A., Sehgal K., Gupta A. et al. (2021) Post-acute COVID-19 syndrome // Nat. Med. 2021 Apr;27(4):601-615. DOI: 10.1038/s41591-021-01283-z

7. Harvey W.T., Carabelli A.M., Jackson B. et al. (2021) SARS-CoV-2 variants, spike mutations and immune escape // Nat. Rev. Microbiol. V. 19. No. 7. P. 409-424. DOI: 10.1038/s41579-021-00573-0

8. V'kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. (2021) Coronavirus biology and replication: implications for SARS-CoV-2 // Nat. Rev. Microbiol. V. 19. No. 3. P.155-170. DOI: 10.1038/s41579-020-00468-6

9. Hu B., Guo H., Zhou P., Shi Z.L. (2021) Characteristics of SARS-CoV-2 and COVID-19 // Nat Rev Microbiol. V. 19. No. 3. P. 141-154. DOI: 10.1038/s41579-020-00459-7

10. Lopez-Leon S., Wegman-Ostrosky T., Perelman,C. et al. (2021) More than 50 long-term effects of COVID-19: a systematic review and meta-analysis // Sci. Rep. V. 11. P. 16144. DOI: 10.1038/s41598-021-95565-8

11. Kemp S.A., Collier D.A., Datir R.P. et al. (2021) SARS-CoV-2 evolution during treatment of chronic infection // Nature. V. 592. No. 7853. P. 277-282. DOI: 10.1038/s41586-021-03291-y

12. Owen D.R., Allerton .CM.N., Anderson A.S. et al. (2021) An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 // Science. V. 374. No. 6575. P. 1586-1593. DOI: 10.1126/science.abl4784

13. Tao K., Tzou P.L., Nouhin J. et al. (2021) The biological and clinical significance of emerging SARS-CoV-2 variants // Nat. Rev. Genet. V. 22. No. 12. P. 757-773. DOI: 10.1038/s41576-021-00408-x

14. Nelde A., Bilich T., Heitmann J.S. et al. (2021) SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition // Nat, Immunol. V. 22. P. 74-85. DOI: 10.1038/s41590-020-00808-x

15. Yong S.J. (2021) Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments // Infect Dis (Lond). V. 53. No. 10. P. 737-754. DOI: 10.1080/23744235.2021

16. Kokic G., Hillen H.S., Tegunov D. et al. (2021) Mechanism of SARS-CoV-2 polymerase stalling by remdesivir // Nat. Commun. V. 12. No. 1. P. 279. DOI: 10.1038/s41467-020-20542-0

17. Han Y., Duan X., Yang L. et al. (2021) Identification of SARS-CoV-2 inhibitors using lung and colonic organoids // Nature. V. 589. No. 7841. P. 270-275. DOI: 10.1038/s41586-020-2901-9

18. Kabinger F., Stiller .C, Schmitzová J. et al. (2021) Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis // Nat. Struct. Mol. Biol. V. 28. No. 9. P. 740-746. DOI: 10.1038/s41594-021-00651-0

19. Osuchowski M.F., Winkler M.S., Skirecki T. et al. (2021) The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity // Lancet Respir. Med. V. 9. No. 6. P. 622-642. DOI: 10.1016/S2213-2600(21)00218-6

20. Braga L., Ali H., Secco I. et al. (2021) Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia // Nature. V. 594. No. 7861. P. 88-93. DOI: 10.1038/s41586-021-03491-6

21. Stukalov A., Girault V., Grass V. et al. (2021) Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV // Nature. V. 594. No. 7862. P. 246-252. DOI: 10.1038/s41586-021-03493-4

22. Qiao J., Li Y.S., Zeng R. et al. (2021) SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model // Science. V. 371. No. 6536. P. 1374-1378. DOI: 10.1126/science.abf1611

23. Jones I,, Roy P. (2021) Sputnik V COVID-19 vaccine candidate appears safe and effective // Lancet. V. 397. No. 10275. P. 642-643. DOI: 10.1016/S0140-6736(21)00191-4

24. Osipiuk J., Azizi S.A., Dvorkin, S. et al. (2021) Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors // Nat. Commun. V. 12. P. 743. DOI: 10.1038/s41467-021-21060-3

25. Rhea E.M., Logsdon A.F., Hansen K.M. et al. (2021) The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice // Nat. Neurosci. V. 24. No. 3. P. 368-378. DOI: 10.1038/s41593-020-00771-8

26. Dejnirattisai W., Zhou D., Ginn H.M. et al. (2021) The antigenic anatomy of SARS-CoV-2 receptor binding domain // Cell. V. 184. No. 8. P. 2183-2200.e22. DOI: 10.1016/j.cell.2021.02.032

27. Zahradník J., Marciano S., Shemesh M. et al. (2021) SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution // Nat. Microbiol. V. 6. No. 9. P. 1188-1198. DOI: 10.1038/s41564-021-00954-4

28. Dittmar M., Lee J.S., Whig K. et al. (2021) Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2 // Cell Rep. 2021. V. 35. No. 1. P. 108959. DOI: 10.1016/j.celrep.2021.108959

29. Günther S., Reinke P.Y.A., Fernández-García Y. et al. (2021) X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease // Science. V. 372. No. 6542. P. 642-646. DOI: 10.1126/science.abf7945

30. Kuo C.J., Chao T.L., Kao H.C. et al. (2021) Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2 // Antimicrob Agents Chemother. V. 65. No. 4. e02577-20. Published 2021 Mar 18. DOI: 10.1128/AAC.02577-20

31. Kuzikov M., Costanzi E., Reinshagen J. et al. (2021) Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen // ACS Pharmacol Transl Sci. V. 4. No. 3. 1096-1110. DOI: 10.1021/acsptsci.0c00216

32. Tompa D.R., Immanuel A., Srikanth S., Kadhirvel S. (2021) Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs // Int. J. Biol. Macromol. V. 172. P. 524-541. DOI: 10.1016/j.ijbiomac.2021.01.076

33. Ren X., Wen W., Fan X. et al. (2021) COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas // Cell. V. 184. No. 7. P. 1895-1913.e19. DOI: 10.1016/j.cell.2021.01.053

34. Tummino T.A., Rezelj V.V., Fischer B. et al. (2021) Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2 // Science. V. 373. No. 6554. P. 541-547. DOI: 10.1126/science.abi4708

35. Jan J.T., Cheng T.R., Juang Y.P. (2021) Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection // Proc. Natl. Acad. Sci. U S A. V. 118. P. e2021579118. DOI: 10.1073/pnas.2021579118

36. Jang W.D., Jeon S., Kim S., Lee S.Y. (2021) Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay // Proc. Natl. Acad. Sc.i U S A. V. 118. P. e2024302118. DOI: 10.1073/pnas.2024302118

37. Muratov E.N. , Amaro R. , Andrade C.H. et al. (2021) A critical overview of computational approaches employed for COVID-19 drug discovery // Chem. Soc. Rev. V. 50. No. 16. P. 9121-9151. DOI: 10.1039/d0cs01065k

38. Al-Aly Z., Xie Y., Bowe B. (2021) High-dimensional characterization of post-acute sequelae of COVID-19 // Nature. V. 594. No. 7862. P. 259-264. DOI: 10.1038/s41586-021-03553-9

39. Bakowski M.A., Beutler N., Wolff K.C. et al. (2021) Drug repurposing screens identify chemical entities for the development of COVID-19 interventions // Nat. Commun. V. 12. P. 3309. DOI: 10.1038/s41467-021-23328-0

40. Mirabelli C., Wotring J.W., Zhang C.J. (2021) Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19 // Proc. Natl. Acad. Sci. U S A. V. 118. P. e2105815118. DOI: 10.1073/pnas.2105815118

41. Schloer S., Brunotte L., Mecate-Zambrano A. et al. (2021) Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro // Br. J. Pharmacol. V. 178. P. 2339-2350. DOI: 10.1111/bph.15418

42. Shyr Z.A., Cheng Y.S., Lo D.C., Zheng W. (2021) Drug combination therapy for emerging viral diseases // Drug Discov. Today. V. 26. P. 2367-2376. DOI: 10.1016/j.drudis.2021.05.008

43. Ng Y.L., Salim C.K., Chu J.J.H. (2021) Drug repurposing for COVID-19: Approaches, challenges and promising candidates // Pharmacol. Ther. V. 228. P. 107930. DOI: 10.1016/j.pharmthera.2021

44. Smith P.F., Dodds M., Bentley D., Yeo K., Rayner C. (2021) Dosing will be a key success factor in repurposing antivirals for COVID-19 // Br. J. Clin. Pharmacol. V. 87. P. 3451-3454. DOI: 10.1111/bcp.14314

45. Chugh H., Awasthi A., Agarwal Y. et al. (2021) A comprehensive review on potential therapeutics interventions for COVID-19 // Eur. J. Pharmacol. V. 890. P. 173741. DOI: 10.1016/j.ejphar.2020.173741

46. Terracciano R., Preianò M., Fregola A. et al. (2021) Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics // Int. J. Mol. Sci. V. 22. P. DOI: 10.3390/ijms22020532

47. Chu J., Xing C., Du Y. et al. (2021) Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication // Nat. Metab. V. 3. P. 1466-1475. DOI: 10.1038/s42255-021-00479-4

48. Yuce M., Cicek E., Inan T. et al. (2021) Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease // Proteins. V. 89. P. 1425-1441. DOI: 10.1002/prot.26164

49. Zeng J., Weissmann F., Bertolin A.P. et al. (2021) Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase // Biochem. J. V. 478. P. 2405-2423. DOI: 10.1042/BCJ20210201

50. Kreutzberger A.J.B., Sanyal A., Ojha R. et al. (2021) Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease // J. Virol. V. 95. P. e0097521. DOI: 10.1128/JVI.00975-21

51. Macip G., Garcia-Segura P., Mestres-Truyol J. et al. (2021) Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition // Med. Res. Rev. V. 42. P. 744-769. DOI: 10.1002/med.21862

52. Wong K.K., Lee S.W.H., Kua K.P. (2021) N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence // J. Inflamm. Res. V. 6. P. 2993-3013. DOI: 10.2147/JIR.S306849

53. Desantis J., Mercorelli B., Celegato M. et al. (2021) Indomethacin-based PROTACs as pan-coronavirus antiviral agents // Eur. J. Med. Chem. V. 226. P. 113814. DOI: 10.1016/j.ejmech.2021.113814

54. Vique-Sánchez J.L. (2021) Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking // Bioorg. Med. Chem. V. 33. P. 116040. DOI: 10.1016/j.bmc.2021.116040

55. Biering S.B., Van Dis E., Wehri E. et al. (2021) Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2 // ACS Infect. Dis. V. 7. P.2337-2351. DOI: 10.1021/acsinfecdis.1c00017

56. Eberle R.J., Olivier D.S., Amaral M.S. et al. (2021) The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CLpro In Vitro // Viruses. V. 13. P. 873. DOI: 10.3390/v13050873

57. Fu W., Chen Y., Wang K. et al. (2021) Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction // Protein Cell. V. 12. P. 586-591. DOI: 10.1007/s13238-020-00803-w

58. Lin M., Dong H.Y., Xie H.Z., Li Y.M., Jia L. (2021) Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions // Drug Discov.Today. V. 26. P. 631-636. DOI: 10.1016/j.drudis.2020.12.010

59. Zakharova M.Y., Kuznetsova A.A., Uvarova V.I. et al. (2021) Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral-Drug Discovery // Front. Pharmacol. V. 12, P. 773198. DOI: 10.3389/fphar.2021.773198

60.Kozlovskaya L.I., Piniaeva A.N., Ignatyev G.M. et al. (2021) Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies // Emerg. Microbes Infect. V. 10. No. 1. P. 1790-1806. DOI: 10.1080/22221751.2021.1971569

61. Savosina P.I., Druzhilovskiy D.S., Poroikov V.V. (2021) COVID-19: Analysis of drug repositioning practice // Pharmaceutical Chemistry Journal. V. 54. P. 989-996. DOI: 10.1007/s11094-021-02308-0

62. Zhuravel S.V., Khmelnitskiy O.K., Burlaka O.O. et al. (2021) Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial // EClinicalMedicine. V. 41. P. 101169. DOI: 10.1016/j.eclinm.2021.101169

63. Letarov A.V., Babenko V.V., Kulikov E.E. (2021) Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection // Biochemistry (Mosc). V. 86. P. 257-261. DOI: 10.1134/S0006297921030032

64. Sulimov V.B., Kutov D.C., Taschilova A.S. et al. (2021) Docking Paradigm in Drug Design // Curr Top Med Chem. V. 21. P. 507-546. DOI: 10.2174/1568026620666201207095626

65. Zarubin A., Stepanov V., Markov A. et al. (2021) Structural Variability, Expression Profile, and Pharmacogenetic Properties of TMPRSS2 Gene as a Potential Target for COVID-19 Therapy // Genes (Basel). V. 12. P. 19. DOI: 10.3390/genes12010019

66. Poloznikov A.A., Nersisyan S.A., Hushpulian D.M. et al. (2021) HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons // Front Pharmacol. V. 11. P. 621054. DOI: 10.3389/fphar.2020.621054

67. Melikhov O., Kruglova T., Lytkina K. et al. (2021) Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals // Ann Rheum Dis. V. 80. P. 1245-1246. DOI: 10.1136/annrheumdis-2021-220049

68. Kozlovskaya L.I., Volok V.P., Shtro A.A. et al. (2021) Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses // Eur. J. Med. Chem. V. 220. P. 113467. DOI: 10.1016/j.ejmech.2021.113467

69. Leneva I., Kartashova N., Poromov A. et al. (2021) Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus // Viruses. V. 13. P. 1665. DOI: 10.3390/v13081665

70. Holms R.D., Ataullakhanov R.I. (2021) Ezrin Peptide Therapy from HIV to COVID: Inhibition of Inflammation and Amplification of Adaptive Anti-Viral Immunity // Int. J. Mol. Sci. V. 22. P. 11688. DOI: 10.3390/ijms222111688

71. Гомазков О.А. (2021) COVID-19. Патогенез сосудистых поражений, или Дьявол кроется в деталях // Москва: Из-во ИКАР. - 72 С. Ссылка

72. Гомазков О.А. (2021) КОВИД-19. Клеточные и молекулярные механизмы поражения мозга // Успехи современной биологии. Т. 141. № 5. С. 457-466. DOI: 10.31857/S0042132421050033

73. Гомазков О.А. (2021) Поражение сосудистого эндотелия как ведущий механизм системной патологии COVID-19 // Успехи современной биологии. Т. 141. № 2. С. 118-127. DOI: 10.31857/S0042132421020058

74. Тарловская Е.И., Арутюнов А.Г., Конради А.О. и др. (2021) Анализ влияния препаратов базовой терапии, применявшихся для лечения сопутствующих заболеваний в период, предшествующий инфицированию, на риск летального исхода при новой коронавирусной инфекции. Данные международного регистра «Анализ динамики Коморбидных заболеваний у пациенТов, перенесшИх инфицироВание SARS-CoV-2» (AКТИВ SARS-CoV-2) // Кардиология. Т. 61. № 9. С. 20-32. DOI: 10.18087/cardio.2021.9.n1680

75. Сулимов А.В., Шихалиев Х.С., Пьянков О.В. и др. (2021) Разработка противовирусных лекарств на основе ингибиторов главной протеазы SARS-CoV-2 // Биомедицинская химия. Т. 67. № 3. С. 259-267. DOI: 10.18097/PBMC20216703259

76. Гайнитдинова В.В., Авдеев С.Н., Мержоева З.М. и др. (2021) Опыт применения N-ацетилцистеина в комплексном лечении среднетяжелой COVID-ассоциированной пневмонии // Пульмонология. Т. 31. С. 21-29. DOI: 10.18093/0869-0189-2021-31-1-21-29

77. Chia C.S.B., Xu W., Shuyi Ng. P. (2021) A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors // ChemMedChem. V. 17. P. e202100576. DOI: 10.1002/cmdc.202100576

1. Halford B. (2022) The path to Paxlovid. How Pfizer scientists transformed an old drug lead into an oral COVID-19 antiviral // ACS Cent. Sci. V. 8. No. 4. P. 405–407. DOI: 10.1021/acscentsci.2c00369

2. Ullrich S., Ekanayake K.B., Otting G., Nitsche C. (2022) Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir // Bioorg. Med. Chem. Lett. V. 62. P. 128629. DOI: 10.1016/j.bmcl.2022.128629

3. Patten J.J., Keiser P.T., Morselli-Gysi D. et al. (2022) Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization // iScience. V. 25. P. 104925. DOI: 10.1016/j.isci.2022.104925

4. Assmus F., Driouich J.S., Abdelnabi R. et al. (2022) Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19 // Microorganisms. V. 10. P. 1639. DOI: 10.3390/microorganisms10081639

5. Bai C., Zhong Q., Gao G.F. (2022) Overview of SARS-CoV-2 genome-encoded proteins // Sci. China Life Sci. V. 65. P. 280-294. DOI: 10.1007/s11427-021-1964-4

6. Hashimoto Y., Suzuki T., Hashimoto K. (2022) Mechanisms of action of fluvoxamine for COVID-19: a historical review // Mol Psychiatry. V. 27. P. 1898-1907. DOI: 10.1038/s41380-021-01432-3

7. Basu D., Chavda V.P., Mehta A.A. (2022) Therapeutics for COVID-19 and post COVID-19 complications: An update // Curr. Res. Pharmacol. Drug Discov. V. 3, P. 100086. DOI: 10.1016/j.crphar.2022.100086

8. Wagoner J., Herring S., Hsiang T.Y. et al. (2022) Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2 // Microbiol. Spectr. V. 10. No. 5. P. e0333122. DOI: 10.1128/spectrum.03331-22

9. Wang X., Sacramento C.Q., Jockusch S. et al. (2022) Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture // Communications biology. V. 5. P. 154. DOI: 10.1038/s42003-022-03101-9

10. Chakraborty C., Sharma A.R., Bhattacharya M., Agoramoorthy G., Lee S.S. (2022) The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies // Front. Pharmacol. V. 12. P. 704205. DOI: 10.3389/fphar.2021.704205

11. Cho C.C., Li S.G., Lalonde T.J. et al. (2022) Drug Repurposing for the SARS-CoV-2 Papain-Like Protease // ChemMedChem. V. 17. P. e202100455. DOI: 10.1002/cmdc.202100455

12. Ledford H. (2022) Hundreds of COVID trials could provide a deluge of new drugs // Nature.V. 603. P. 25-27. DOI: 10.1038/d41586-022-00562-0

13. Hua Y., Dai X., Xu Y. et al. (2022) Drug repositioning: Progress and challenges in drug discovery for various diseases // Eur. J. Med. Chem. V. 234. P. 114239. DOI: 10.1016/j.ejmech.2022

14. Shytaj I,L,, Fares M,, Gallucci L. et al. (2022) Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters // mBio. V. 13. P. e0370521. DOI: 10.1128/mbio.03705-21

15. Prieto Santamaría L., Díaz Uzquiano M., Ugarte Carro E. et al. (2022) Integrating heterogeneous data to facilitate COVID-19 drug repurposing // Drug Discov. Today. V. 27. P. 558-566. DOI: 10.1016/j.drudis.2021.10.002

16. Ngan D.K., Xu T., Xia M., Zheng W., Huang R. (2022) Repurposing drugs as COVID-19 therapies: A toxicity evaluation // Drug Discov. Today. V. 27. P. 1983-1993. DOI: 10.1016/j.drudis.2022.04.001

17. Chiu W., Verschueren L., Van den Eynde C. et al. (2022) Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures // J. Med. Virol. V. 94. P. 3101-3111. DOI: 10.1002/jmv.27683

18. Jonsdottir H.R., Siegrist D., Julien T. et al. (2022) Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro // Biomed. Pharmacother. V. 150. P. 113058. DOI: 10.1016/j.biopha.2022.113058

19. Yip A.J.W., Low Z.Y., Chow V.T.K., Lal S.K. (2022) Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity // Viruses. V. 14. P. 1345. DOI: 10.3390/v14061345

20. Robinson B.W.S., Tai A., Springer K. (2022) Why we still need drugs for COVID-19 and can't just rely on vaccines // Respirology. V. 27. P. 109-111. DOI: 10.1038/10.1111/resp.14199

21. Ferraresi A., Isidoro C. (2022) Will Omics Biotechnologies Save Us from Future Pandemics? Lessons from COVID-19 for Vaccinomics and Adversomics // Biomedicines. V. 11. P. 52. DOI: 10.3390/biomedicines11010052

22. Shcherbakov D., Baev D., Kalinin M. et al. (2022) Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors // ACS Med. Chem. Lett. V. 13. No. 1. P. 140–147. DOI: 10.1021/acsmedchemlett.1c00299

23. Narayanan A., Narwal M., Majowicz S.A. et al. (2022) Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay // Commun. Biol. V. 5. P. 169. DOI: 10.1038/s42003-022-03090-9

24. Chupakhin O.N., Rusinov V..L, Varaksin M.V. et al. (2022) Triazavirin-A Novel Effective Antiviral Drug // Int. J. Mol. Sci. V. 23. P. 14537. DOI: 10.3390/ijms232314537

25. Kostyusheva A., Brezgin S., Babin Y. et al. (2022) CRISPR-Cas systems for diagnosing infectious diseases // Methods. V. 203. P. 431-446. DOI: 10.1016/j.ymeth.2021.04.007

26. Nersisyan S., Zhiyanov A., Shkurnikov M., Tonevitsky A. (2022) T-CoV: a comprehensive portal of HLA-peptide interactions affected by SARS-CoV-2 mutations // Nucleic Acids Res. V. 50(D1). P. D883-D887. DOI: 10.1093/nar/gkab701

27. Bagrov D.V., Glukhov G.S., Moiseenko A.V. et al. (2022) Structural characterization of β-propiolactone inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles // Microsc Res Tech. V. 85. P. 562-569. DOI: 10.1002/jemt.23931

28. Kolpakov F., Akberdin I., Kiselev I. et al. (2022) BioUML-towards a universal research platform // Nucleic Acids Res. V. 50(W1). P. W124–31. DOI: 10.1093/nar/gkac286

29. Puhl A.C., Gomes G.F., Damasceno S. et al. (2022) Pyronaridine Protects against SARS-CoV-2 Infection in Mouse // ACS Infect Dis. V. 8. P. 1147-1160. DOI: 10.1021/acsinfecdis.2c00091

30. Shkoda A.S., Gushchin V..A, Ogarkova D.A. et al. (2022) Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance // Vaccines (Basel). V. 10. P. 938. DOI: 10.3390/vaccines10060938

31. Fomenko V.V., Rudometova N.B., Yarovaya O.I. et al. (2022) Synthesis and In Vitro Study of Antiviral Activity of Glycyrrhizin Nicotinate Derivatives against HIV-1 Pseudoviruses and SARS-CoV-2 Viruses // Molecules. V. 27. P. 295. DOI: 10.3390/molecules27010295

32. Makarov V.A., Popov V.O. (2022) PDSTP Is the First Drug in Class to Treat Coronavirus Infection // Her. Russ. Acad. Sci. V. 92. P. 488-490. DOI: 10.1134/S1019331622040190

33. Ivashchenko A.A., Zagribelnyy B.A., Ivanenkov Y.A. et al. (2022) The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2 // Molecules. V. 27. P. 4975. DOI: 10.3390/molecules27154975

34. Гомазков О.А. (2022) Нейропилин – новый игрок в патогенезе COVID-19 // Нейрохимия. Т. 39. № 2. С. 124-130. DOI: 10.31857/S1027813322020066

35. Гомазков О.А. (2022) Нейротропизм как механизм поражающего действия коронавируса // Успехи современной биологии. Т. 142. № 4. С. 406-416. DOI: 10.31857/S0042132422040068

36. Иванова Я.О., Воронина А.И., Скворцов В.С. (2022) Предсказание ингибирования главной протеазы SARS-CoV-2 c учётом фильтрации данных о положении лигандов // Биомедицинская химия. Т. 68. № 6. С. 444-458. DOI: 10.18097/PBMC20226806444

37. Oh C.K., Nakamura T., Beutler N. et al. (2023) Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection // Nature chemical biology. V. 19. P. 275-283. DOI: 10.1038/s41589-022-01149-6

38. Silva V., Radic M. (2022) COVID-19 Pathology Sheds Further Light on Balance between Neutrophil Proteases and Their Inhibitors // Biomolecules. V. 13. P. 82. DOI: 10.3390/biom13010082

39. Zhang Y., Juhas M., Kwok C.K. (2022) Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19 // Trends Biotechnol. V. 41. P. 528-544. DOI: 10.1016/j.tibtech.2022.07.012

40. Lundstrom K., Hromić-Jahjefendić A., Bilajac E. et al. (2022) COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity // Cell Signal. V. 101. P. 110495. DOI: 10.1016/j.cellsig.2022.110495

41. Ng W.H., Tang P.C.H., Mahalingam S., Liu X. (2023) Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2 // Br. J. Pharmacol. V. 180. P. 133-143. DOI: 10.1111/bph.15987

42. Jahirul Islam M., Nawal Islam N., Siddik Alom M. et al. (2022) A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites // Immunobiology. V. 228. P. 152302. DOI: 10.1016/j.imbio.2022.152302

43. Lim S.P. (2022) Targeting SARS-CoV-2 and host cell receptor interactions // Antiviral Res. V. 210. P. 105514. DOI: 10.1016/j.antiviral.2022.105514

44. Bilezikian J.P., Binkley N., De Luca H.F. (2023) Consensus and controversial aspects of vitamin D and COVID-19 // The Journal of Clinical Endocrinology & Metabolism. V. 108. P. 1034-1042. DOI: 10.1210/clinem/dgac719

44. Bilezikian J.P., Binkley N., De Luca H.F. (2023) Consensus and controversial aspects of vitamin D and COVID-19 // The Journal of Clinical Endocrinology & Metabolism. V. 108. P. 1034-1042. DOI: 10.1210/clinem/dgac719

1. Saravolatz L.D., Depcinski S., Sharma M. (2023) Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs // Clin. Infect. Dis. V. 76. P. 165-171. DOI: 10.1093/cid/ciac180

2. Zheng Q., Ma P., Wang M. et al. (2023) Efficacy and safety of Paxlovid for COVID-19:a meta-analysis // J. Infect. V. 86, P. 66-117. DOI: 10.1016/j.jinf.2022.09.027

3. Murakami N., Hayden R., Hills T. et al. (2023) Therapeutic advances in COVID-19 // Nat. Rev. Nephrol. V. 19. P. 38-52. DOI: 10.1038/s41581-022-00642-4

4. Msemburi W., Karlinsky A., Knutson V.et al. (2023) The WHO estimates of excess mortality associated with the COVID-19 pandemic // Nature. V. 613. P. 130-137. DOI: 10.1038/s41586-022-05522-2

5. Pilla Reddy V., El-Khateeb E., Jo H. et al. (2023) Pharmacokinetics under the COVID-19 storm // Br. J. Clin. Pharmacol. V. 89. P. 158-186. DOI: 10.1111/bcp.14668

6. Rannard S.P., McDonald T.O., Owen A. (2023) Chasing COVID-19 chemotherapeutics without putting the cart before the horse // Br. J. Clin. Pharmacol. V. 89. P. 421-423. DOI: 10.1111/bcp.14575

7. Su J., Shen S., Hu Y. et al. (2023) SARS-CoV-2 ORF3a inhibits cGAS-STING-mediated autophagy flux and antiviral function // J. Med. Virol. V. 95. P. e28175. DOI: 10.1002/jmv.28175

8. Pérez-Vargas J., Shapira T., Olmstead A.D. et al. (2023) Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics // Antiviral research. V. 209. Article ID: 105484. DOI: 10.1016/j.antiviral.2022.105484

9. Davis H.E., McCorkell L., Vogel J.M., Topol E.J. (2023) Long COVID: major findings, mechanisms and recommendations // Nat. Rev. Microbiol. V. 21. P. 133-146 DOI: 10.1038/s41579-022-00846-2

10. Jahirul Islam M., Nawal Islam N., Siddik Alom M., Kabir M., Halim M.A. (2023) A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites // Immunobiology. V. 228. P. 152302. DOI: 10.1016/j.imbio.2022.152302

11. Boytz R., Słabicki M., Ramaswamy S. et al. (2023) Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy // J. Med. Virol. V. 95. P. e28157. DOI: 10.1002/jmv.28157

12. Frigerio R., Musicò A., Strada A. et al. (2023) Epitope Mapping on Microarrays Highlights a Sequence on the N Protein with Strong Immune Response in SARS-CoV-2 Patients // Methods Mol Biol. V. 2578. P. 209-217. DOI: 10.1007/978-1-0716-2732-7_15

13. Liu X., Hasan M.R., Ahmed .KA., Hossain M.Z. (2023) Machine learning to analyse omic-data for COVID-19 diagnosis and prognosis // BMC Bioinformatics. V. 24. P.7. DOI: 10.1186/s12859-022-05127-6

14. Sui L., Li L., Zhao Y. et al. (2023) Host cell cycle checkpoint as antiviral target for SARS-CoV-2 revealed by integrative transcriptome and proteome analyses // Signal Transduct. Target. Ther. V. 8. P. 21. DOI: 10.1038/s41392-022-01296-1

15. Pérez-Vargas J., Shapira T., Olmstead A.D. et al. (2023) Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics // Antiviral research. V. 209. Article ID: 105484. DOI: 10.1016/j.antiviral.2022.105484

16. Smith E., Davis-Gardner M.E., Garcia-Ordonez R.D. et al. (2023) High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2 // SLAS Discov. V. 28. P. 95-101. DOI: 10.1016/j.slasd.2023.01.001

17. Omenn G.S., Lane L., Overall C.M. et al. (2023) The 2023 Report on the Proteome from the HUPO Human Proteome Project // J. Proteome Res. DOI: 10.1021/acs.jproteome.3c00591

18. Brindani N., Munafò F., Menichetti A. et al. (2023) Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors // Bioorg. Med. Chem. V. 80. P. 117179. DOI: 10.1016/j.bmc.2023.117179

19. Vuorio A., Raal F., Kovanen P.T. (2023) Drug-drug interaction with oral antivirals for the early treatment of COVID-19 // Int. J. Infect. Dis. V. 127. P. 171-172. DOI: 10.1016/j.ijid.2022.11.039

20. Collins F., Adam S., Colvis C. et al. (2023) The NIH-led research response to COVID-19 // Science. V. 379. P. 441-444. DOI: 10.1126/science.adf5167

21. Joshi R.P., Schultz K.J., Wilson J.W. et al. (2023) AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2 // J. Chem. Inf. Model. V. 63. P. 1438-1453. DOI: 10.1021/acs.jcim.2c01377

22. Wamser R., Pach S., Arkona C. et al. (2023) A Critical Study on Acylating and Covalent Reversible Fragment Inhibitors of SARS-CoV-2 Main Protease Targeting the S1 Site with Pyridine // ChemMedChem. V. 22. Article ID: e202200635. DOI: 10.1002/cmdc.202200635

23. Gentile F., Oprea T.I,, Tropsha A., Cherkasov A. (2023) Surely you are joking, Mr Docking! // Chem. Soc Rev. Epub ahead of print. DOI: 10.1039/d2cs00948j

24. Davis H.E., McCorkell L., Vogel J.M., Topol E.J. (2023) Long COVID: major findings, mechanisms and recommendations // Nat. Rev. Microbiol. V. 13. P. 1–14. DOI: 10.1038/s41579-022-00846-2

25. Prasetiya F.S., Destiarani W., Nuwarda R.F. et al. (2023) The nanomolar affinity of C-phycocyanin from virtual screening of microalgal bioactive as potential ACE2 inhibitor for COVID-19 therapy // J. King. Saud. Univ. Sci. V. 35. P. 102533. DOI: 10.1016/j.jksus.2022.102533

26. Malone B.F., Perry J.K., Olinares P.D.B. et al. (2023) Structural basis for substrate selection by the SARS-CoV-2 replicase // Nature. V. 614. P. 781–787. DOI: 10.1038/s41586-022-05664-3

27. Panahi Y., Gorabi A.M., Talaei S. et al. (2023) An overview on the treatments and prevention against COVID-19 // Virology Journal. V. 20. P. 1-29. DOI: 10.1186/s12985-023-01973-9

28. Khan A.M., Atia-Tul-Wahab, Farooq S. et al. (2023) Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (Mpro) by using STD-NMR spectroscopy, in silico studies and antiviral assays // Int. J. Biol. Macromol. V. 234. P. 123540. DOI: 10.1016/j.ijbiomac.2023.123540

29. Russell C.D., Lone N.I., Baillie J.K. (2023) Comorbidities, multimorbidity and COVID-19 // Nature medicine. V. 29. P. 334-343. DOI: 10.1038/s41591-022-02156-9

30. Chaguza C., Hahn A.M., Petrone M.E. et al. (2023) Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection // Cell Reports Medicine V. 4. Article ID: 100943. DOI: 10.1016/j.xcrm.2023.100943

31. Wang X., Wang H., Yin G. et al. (2023) Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages // Heliyon. V. 9. P. e14059. DOI: 10.1016/j.heliyon.2023.e14059

32. Lundstrom K., Hromić-Jahjefendić A., Bilajac E. et al. (2023) COVID-19 signalome: Potential therapeutic interventions // Cell Signal. V. 103. Article ID: 110559. DOI: 10.1016/j.cellsig.2022.110559

33. Chatterjee S., Nalla L.V., Sharma M et al. (2023) Association of COVID-19 with Comorbidities: An Update // ACS Pharmacol. Transl. Sci. V. 6. P. 334-354. DOI: 10.1021/acsptsci.2c00181

34. Pozzi C., Vanet A., Francesconi V. et al. (2023) Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective // J. Med. Chem. V. 66. P. 3664-3702. DOI: 10.1021/acs.jmedchem.2c01229

35. Kovacic S., Ng K., Pandey M. et al. (2023) A. Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors // J. Chem. Inf. Model. V. 63. P. 2158-2169. DOI: 10.1021/acs.jcim.2c01641

36. Wang R., Lee J.H., Kim J. et al. (2023) SARS-CoV-2 restructures host chromatin architecture // Nat. Microbiol. V. 8. P. 679-694. DOI: 10.1038/s41564-023-01344-8

37. Bekheit M.S., Panda S.S., Girgis A.S. (2023) Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2 // Eur. J. Med. Chem. V. 252. P. 115292. DOI: 10.1016/j.ejmech.2023.115292

38. Hernán M.A., Del Amo J. (2023) Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19 // Ann. Intern. Med. V. 176. P. 556-560. DOI: 10.7326/M22-3582

39. Avdonin P.P., Rybakova E.Y., Trufanov S.K. et al. (2023) SARS-CoV-2 Receptors and Their Involvement in Cell Infection // Biochem. Moscow Suppl. Ser. A. V. 17. P. 1–11. DOI: 10.1134/S1990747822060034

40. Stefanelli I., Corona A., Cerchia C. et al. (2023) Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination // Eur. J. Med. Chem. V. 253. P. 115311. DOI: 10.1016/j.ejmech.2023.115311

41. Votto M., Castagnoli R., Marseglia G.L. et al. (2023) COVID-19 and autoimmune diseases: is there a connection? // Current Opinion in Allergy and Clinical Immunology. V. 23. P. 185-192. DOI: 10.1097/ACI.0000000000000888

42. Shin Y.S., Lee J.Y., Jeon S. et al. (2023) Discovery of 2-aminoquinolone acid derivatives as potent inhibitors of SARS-CoV-2 // Bioorg. Med. Chem. Lett. V.85. P. 129214. DOI: 10.1016/j.bmcl.2023.129214

43. Smith E., Davis-Gardner M.E., Garcia-Ordonez R.D. et al. (2023) High Throughput Screening for Drugs that Inhibit 3C-Like Protease in SARS-CoV-2 // SLAS Discov. V. 13. P. S2472-5552(23)00001-1. DOI: 10.1016/j.slasd.2023.01.001

44. Kronenberger T., Laufer S.A., Pillaiyar T. (2023) COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease // Drug Discov. Today. V. 28. P. 103579. DOI: 10.1016/j.drudis.2023.103579. DOI: 10.1016/j.drudis.2023.103579

45. Markov P.V., Ghafari M., Beer M. et al (2023) The evolution of SARS-CoV-2 // Nat. Rev. Microbiol. V. 21. P. 361-379. DOI: 10.1038/s41579-023-00878-2

46. Ghorbanali Z., Zare-Mirakabad F., Akbari M. et al. (2023) DrugRep-KG: Toward Learning a Unified Latent Space for Drug Repurposing Using Knowledge Graphs // J. Chem. Inf. Model. V. 63. P. 2532-2545. DOI: 10.1021/acs.jcim.2c01291

47. Kumar S., Basu M., Ghosh P. et al. (2023) COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery // Genes Dis. V. 10. P. 1402-1428. DOI: 10.1016/j.gendis.2022.12.019

48. Hersi F., Sebastian A., Tarazi H. et al. (2023) Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19 // Eur. J. Med. Chem. V. 254. P. 115380. DOI: 10.1016/j.ejmech.2023.115380

49. Li G., Hilgenfeld R., Whitley R. et al. (2023) Therapeutic strategies for COVID-19: progress and lessons learned // Nat. Rev. Drug Discov. V. 22. P. 449–475. DOI: 10.1038/s41573-023-00672-y

50. Vaz E.S., Vassiliades S.V., Giarolla J. et al. (2023) Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies // Eur. J. Clin. Pharmacol. V. 79. P. 723-751. DOI: 10.1007/s00228-023-03486-4

51. Su Y., Wu J., Li X. et al. (2023) DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19 // Comput. Biol. Med. V. 159. P. 106969. DOI: 10.1016/j.compbiomed.2023.106969

52. von Delft A., Hall M.D., Kwong A.D. et al. (2023) Accelerating antiviral drug discovery: lessons from COVID-19 // Nat. Rev. Drug Discov. V. 22. P. 585–603. DOI: 10.1038/s41573-023-00692-8

53. Pang X., Xu W., Liu Y. et al. (2023) The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022 // Eur. J. Med. Chem. V. 257. P. 115491. DOI: 10.1016/j.ejmech.2023.115491

54. Mehyar N. (2023) Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of invitro studies // J. Virus Erad. V. 9. P. 100327. DOI: 10.1016/j.jve.2023.100327

55. Ahmed M.S., Farag A.B., Boys I.N. (2023) FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms // Biomed. Pharmacother. V. 162. Article ID: 114614. DOI: 10.1016/j.biopha.2023.114614

56. Augustin Y., Staines H.M., Velavan T.P. et al. (2023) Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews // Br. Med. Bull. V. 147. P. 31-49. DOI: 10.1093/bmb/ldac037

57. Brian Chia C.S., Pheng Lim S. (2023) A Patent Review on SARS Coronavirus Papain-Like Protease (PLpro) Inhibitors // ChemMedChem. V. 18. P. e202300216. DOI: 10.1002/cmdc.202300216

58. Peterson A.A., Liu D.R. (2023) Small-molecule discovery through DNA-encoded libraries // Nat. Rev. Drug Discov. V. 22. P. 699–722. DOI: 10.1038/s41573-023-00713-6

59. Sebők S., Gyires K. (2023) Long COVID and possible preventive options // Inflammopharmacol. V. 31. P. 2807–2817. DOI: 10.1007/s10787-023-01204-1

60. Viskupicova J., Rezbarikova P., Kovacikova L. et al. (2023) Inhibitors of SARS-CoV-2 main protease: Biological efficacy and toxicity aspects // Toxicol. In Vitro. V. 92. P. 105640. DOI: 10.1016/j.tiv.2023.105640

61. Brett J., Bahceci D., Lipworth W. et al. (2023) Can old drugs learn new tricks? Achieving registration and public subsidy listing for off-patent medicines with novel therapeutic applications // Intern. Med. J. V. 53. P. 1284-1287. DOI: 10.1111/imj.16159

62. Dinda B., Dinda M., Dinda S. et al. (2023) An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms // Eur. J. Med. Chem. V. 258. P. 115629. DOI: 10.1016/j.ejmech.2023.115629

63. Yao Y., Zhang Y., Li Z. et al. (2023) A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism // Biochem. Biophys. Res. Commun. V. 675. P. 113-121. DOI: 10.1016/j.bbrc.2023.07.018

64. Tan B., Sacco M., Tan H. et al. (2023) Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors // Eur. J. Med. Chem. V. 259. P. 115667. DOI: 10.1016/j.ejmech.2023.115667

65. Puhl A.C., Lane T.R., Ekins S. (2023) Learning from COVID-19: How drug hunters can prepare for the next pandemic // Drug Discov. Today. V. 28. P. 103723. DOI: 10.1016/j.drudis.2023.103723

66. Xu L., Chen R., Liu J. et al. (2023) Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery // Drug Discov. Today. V. 28. P. 103727. DOI: 10.1016/j.drudis.2023.103727

67. Elkashlan M., Ahmad R.M., Hajar M. et al. (2023) A review of SARS-CoV-2 drug repurposing: databases and machine learning models // Front. Pharmacol. V. 14. Article ID: 1182465. DOI: 10.3389/fphar.2023.1182465

68. Zhang F., Luna A., Tan T. et al. (2023) COVIDpro: Database for Mining Protein Dysregulation in Patients with COVID-19 // J. Proteome Res. V. 22. P. 2847-2859. DOI: 10.1021/acs.jproteome.3c00092

69. Kushwaha N.D., Mohan J., Kushwaha B. et al. (2023) A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19 // Eur. J. Med. Chem. V. 260. P. 115719. DOI: 10.1016/j.ejmech.2023.115719

70. Pitsillou E., Beh R.C., Liang J.J. et al. (2023) EpiMed Coronabank Chemical Collection: Compound selection, ADMET analysis, and utilisation in the context of potential SARS-CoV-2 antivirals // J. Mol. Graph. Model. V. 125. P. 108602. DOI: 10.1016/j.jmgm.2023.108602

71. Valipour M., Irannejad H., Keyvani H. (2023) An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead // ACS Pharmacol. Transl. Sci. V. 6. P. 1248-1265. DOI: 10.1021/acsptsci.3c00121

72. Zhang F.M., Huang T., Wang F. et al. (2023) Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19 // Eur. J. Med. Chem. V. 260. P. 115721. DOI: 10.1016/j.ejmech.2023.115721

73. Martin H.J., Melo-Filho C.C., Korn D. et al. (2023) A. Small molecule antiviral compound collection (SMACC): A comprehensive, highly curated database to support the discovery of broad-spectrum antiviral drug molecules // Antiviral Res. V.217. Article ID: 105620. DOI: 10.1016/j.antiviral.2023.105620

74. Boytz R., Słabicki M., Ramaswamy S. et al. (2023) Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: repurposing clinically available drugs for COVID‐19 therapy // Journal of medical virology. V. 95. Article ID: e28157. DOI: 10.1002/jmv.28157

75. Wilks S.H., Mühlemann B., Shen X. et al. (2023) Mapping SARS-CoV-2 antigenic relationships and serological responses // Science. V. 382. Article ID: eadj0070. DOI: 10.1126/science.adj0070

76. Zhou Y., Liu Y., Gupta S. et al. (2023) A comprehensive SARS-CoV-2–human protein–protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets // Nature biotechnology. V. 41. P. 128-139. DOI: 10.1038/s41587-022-01474-0

77. Kim D.K., Weller B., Lin C.W. et al. (2023) A proteome-scale map of the SARS-CoV-2–human contactome // Nature Biotechnology. V. 41. P. 140-149. DOI: 10.1038/s41587-022-01475-z

78. Schimunek J., Seidl P., Elez K. et al. (2023) A community effort in SARS-CoV-2 drug discovery // Molecular Informatics, 2023 Oct 13. Article ID: e202300262. DOI: 10.1002/minf.202300262

79. Zhang Y., Li Y. (2023) Clinical Translation of Aptamers for COVID-19 // J. Med. Chem. V. 66. P. 16568–16578. DOI: 10.1021/acs.jmedchem.3c01607

80. Chen J., Zhou Y., Wei X. et al. (2023) Development of Pan-Anti-SARS-CoV-2 Agents through Allosteric Inhibition of nsp14/nsp10 Complex // ACS Infect. Dis. DOI: 10.1021/acsinfecdis.3c00356

81. Iketani S., Mohri H., Culbertson B. et al. (2023) Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir // Nature. V. 613. P. 558-564. DOI: 10.1038/s41586-022-05514-2

82. Sang X., Wang J., Zhou J. et al. (2023) A Chemical Strategy for the Degradation of the Main Protease of SARS-CoV-2 in Cells // J. Am. Chem. Soc. V. 145. P. 27248–27253. DOI: 10.1021/jacs.3c12678

83. Tropsha A., Isayev O., Varnek A. et al. (2023) Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR // Nat. Rev. Drug Discov. DOI: 10.1038/s41573-023-00832-0

84. Oktavianawati I., Santoso M., Bakar M.F.A. et al. (2023) Recent progress on drugs discovery study for treatment of COVID-19: repurposing existing drugs and current natural bioactive molecules // Appl. Biol. Chem. V. 66. P. 89. DOI: 10.1186/s13765-023-00842-x

85. Teng O., Quek A.M.L., Nguyen T.M. et al. (2023) Biomarkers of early SARS-CoV-2 infection before the onset of respiratory symptoms // Clin. Microbiol. Infect. DOI: 10.1016/j.cmi.2023.12.024

1. Agyarko R., Al Slail F., Garrett D.O. et al. (2024) The imperative for global cooperation to prevent and control pandemics // In: Modernizing Global Health Security to Prevent, Detect, and Respond. Academic Press. P. 53-69. Paperback ISBN: 9780323909457 / eBook ISBN: 9780323909464

2. Wu A., Shi K., Wang J. et al. (2024) Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors // Eur. J. Med. Chem. V. 263. Article ID: 115923. DOI: 10.1016/j.ejmech.2023.115923

3. Pradelle A., Mainbourg S., Provencher S. et al. (2024) Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate // Biomed. Pharmacother. V. 171. Article ID: 116055. DOI: 10.1016/j.biopha.2023.116055

4. Marrone G., Covino M., Merra G. et al. (2024) Ursodeoxycholic acid does not affect the clinical outcome of SARS-CoV-2 infection: A retrospective study of propensity score-matched cohorts // Liver Int. V. 44. P. 83-92. DOI: 10.1111/liv.15736

5. Nandi S., Kumar M., Saxena A.K. (2024) QSAR of SARS-CoV-2 main protease inhibitors utilizing theoretical molecular descriptors // Letters in Drug Design & Discovery. V. 21. P. 116-132. DOI: 10.2174/1570180820666221214151614

6. Zanini G., Selleri V., Roncati L. et al. (2024) Vascular “long COVID”: a new vessel disease? // Angiology. V. 75. P. 8-14. DOI: 10.1177/00033197231153204

7. Boccellino M. (2024) COVID-19 pandemic: therapeutic strategies and vaccines // Int. J. Mol. Sci. V. 25. Article ID: 556. DOI: 10.3390/ijms25010556

8. Bogacheva M.S., Kuivanen S., Potdar S. et al. (2024) Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome // Antiviral Res.. DOI: 10.1016/j.antiviral.2024.105813

9. Zhang D., Kukkar D., Kim K.H. et al. (2024) A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19 // Int. J. Biol. Macromol. V. 259. P. 129284. DOI: 10.1016/j.ijbiomac.2024.129284